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A B S T R A C T
Introduction. The recent sophisticated diagnostic procedures aimed at identifying the exact cause of erectile
dysfunction (ED) are often complicated in clinical application, invasive, or highly expensive. Microalbuminuria, a
test easy to perform and of low cost, is a marker of extensive endothelial dysfunction, and it has been suggested to
be linked to ED.
Aim. The aim of this study was to investigate the eventual role of microalbuminuria in differentiating patients with
arteriogenic and non arteriogenic ED.
Methods. The diagnosis of ED was based on the International Index of Erectile Function 5-questionnaire, and
patients were classiﬁed as arteriogenic (N = 29) and non-arteriogenic (N = 49) in relation to the results of echo-
color-doppler examination of cavernosal arteries in basal conditions and after intracavernous injection of 10 mg
prostaglandin E1.
Main Outcome Measures. The microalbuminuria of 78 males without the most common atheriosclerotic risks and
with ED was measured.
Results. Microalbuminuria, deﬁned as urinary albumin/creatinine ratio, was not signiﬁcantly (P > 0.05) different
between patients of the two groups.
Conclusions. Our data show that in ED patients the cavernosal arteries damage, as assessed by dynamic echo-color-
doppler, may be independent on or precede extensive endothelial dysfunction, and that microalbuminuria cannot be
predictive of penile arteriogenic etiology. Barassi A, Pezzilli R, Morselli-Labate AM, Porreca W, Piediferro G,
Ciociola F, Colpi G, and Melzi d’Eril G. Evaluation of microalbuminuria in patients with erectile dysfunc-
tion. J Sex Med 2010;7:1224–1228.
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Introduction
Erectile dysfunction (ED) has been deﬁned bythe National Institute of Health as the inabil-
ity to achieve and/or to maintain penile erection
of sufﬁcient quality to allow a satisfactory sexual
intercourse [1]. It has been estimated to affect 20
million to 30 million men in the United States, and
that approximately 5–20% of men, complain of
moderate to severe ED [2]. Although penile erec-
tion is the result of a complex and coordinated
series of events involving vascular response, neu-
ronal pathways, and psychosomatic stimulation,
the proper function of the vascular endothelium is
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essential to achieving and maintaining penile erec-
tion. In fact, recent data reveal more than 80% of
ED has an organic basis, with vascular disease
being the most common etiology [3,4]. A function-
ing NO pathway is a primary determinant of
smooth muscle tone, arterial inﬂow, and restricted
venous outﬂow in the physiology of erection. Dis-
ruption of any of these factors can lead to ED.
Endothelial dysfunction, which is associated with
impaired release and activity of nitric oxide (NO),
underlies the pathophysiology of vascular ED
[5,6]. The small diameter of the cavernosal arteries
and the high content of endothelium and smooth
muscle on a per-gram tissue basis, compared with
other organs, may make penile vascular bed a sen-
sitive indicator of systemic vascular disease [7]. It
follows that ED can be a result of any number of
structural, like minimal occlusion of cavernosal
arteries, or functional, like impaired smooth
muscle relaxation, abnormalities in the penile vas-
cular bed [8].
The study by Nathan et al. [9] illustrates the
relation of microalbuminuria to vascular complica-
tions such as intima-media thickening. The validity
of microalbuminuria as an index is further
addressed by Perkins et al. [10]. The amount of
albumin excreted in the urine over a 24-h period
was once considered the “gold standard” for deﬁn-
ingmicroalbuminuria.However, 24-h urine collec-
tions are cumbersome and subject to error because
of inaccurate timing and/or incompleteness. To
avoid these adverse inﬂuences, 24-h urinary
albumin excretion is replaced by the ratio of urinary
albumin concentration to urinary creatinine con-
centration (UACR) [11].Hence,microalbuminuria
was deﬁned as UACR cutoff of 30–299 mg/g
according to the criteria of the American Diabetes
Association [12]. Assessment of microalbuminuria
is particularly important in diagnosing diabetes
kidney disease because low levels of albuminuria are
an early clinical manifestation of diabetic nephr-
opathy that may present several years before devel-
opment of a diminished glomerular ﬁltration rate
[13]. Furthermore, microalbuminuria alone has
been associated with an increased risk of cardiovas-
cular disease, both in patients with and without
diabetes mellitus [14–16]; moreover, microalbu-
minuria is a signiﬁcant risk factor for cardiovascular
mortality in type 1 [17] and 2 diabetes [18], as well
as in the non-diabetic population [19]. Accordingly,
microalbuminuria can be considered a marker of
extensive endothelial dysfunction and plays a key
role as a potential cardiovascular and atheroscle-
rotic risk factor [20].
The coincidence of microalbuminuria and
extrarenal vascular damage in diabetic patients led
to the hypothesis that albuminuria does not only
reﬂect a state of glomerular, but also generalized
endothelial dysfunction [21]. Many recent studies
[22] demonstrate the usefulness of microalbumin-
uria as a valuable and clinically relevant tool for the
identiﬁcation of individual patients at risk for the
development of end-organ damage, for example,
systemic cardiovascular disease. Therefore, the
endothelium appears to be the link between meta-
bolic changes and physiological dysfunction. In
accordance with the aforementioned data, we
hypothesized that microalbuminuria could be a
marker of vascular ED in a population free of the
most common atheriosclerotic risks. The beneﬁts
of using microalbuminuria to screen for endothe-
lial injury are that it is inexpensive and the results
are available rapidly.
The aim of this study was to investigate the
relationship between arteriogenic ED and
microalbuminuria, as a marker of endothelial dys-
function, in a group of patients without known
clinical risk factors for vascular pathology.
Materials and Methods
Erectile function was assessed on an appropriate
clinical work-up study and by using the abridged
ﬁve-item version of the International Index of
Erectile Function questionnaire (IIEF-5), a vali-
dated, self administered questionnaire [23,24].
Seventy-eight men (mean age 44.1 years, range
24–62 years) underwent echo-color-doppler
examination of cavernosal arteries in basal condi-
tions and after intracavernous injection of 10 mg
prostaglandin E1, and the peak systolic velocity
(PSV) and end-diastolic velocity (EDV) were
recorded 5, 10, 15, 20, and 25 minutes after the
drug injection into the proximal portion of the
penis. PSV and EDV are reported as the mean of
the values measured in both cavernosal arteries.
Patients were classiﬁed as non-arteriogenic when
their PSV was 35 cm/sec, or <35 cm/sec but
>25 cm/sec with concomitant EDV 0 cm/sec,
and arteriogenic when their PSV was 20 cm/sec
[25]. Resistance index (RI) >0.80 is considered
normal. The erection quality was estimated
20 minutes after each injection. If a patient
appeared stressed, he was given a second injection
of the same dose of prostaglandin E1 and all mea-
surements were repeated. The procedure was
repeated in one non-arteriogenic and two arterio-
genic patients without changing the outcomes.
Microalbuminuria and Erectile Dysfunction 1225
J Sex Med 2010;7:1224–1228
None of the patients had clinical evidence of coro-
nary artery disease, diabetes mellitus, hyperten-
sion, malignancy, renal failure, congestive heart
failure, systemic inﬂammatory disease, or arrhyth-
mias. In all patients, we measured the testosterone
and prolactin serum levels, and only patients
without endocrine risk factors were considered in
the present study. In accordance with Helsinki
Declaration II, the design and execution of the
experiment were explained thoroughly to the par-
ticipants, and informed consent was obtained. The
Mann-Whitney and the Fisher’s exact tests were
applied to analyze data by running the SPSS
(Version 12.0 for Windows) statistical package.
Urinary microalbumin concentration was mea-
sured in duplicate in the morning samples on a
Behring Nephelometer II analyzer (Dade
Behring). The within-run (N = 40) and the
between-run coefﬁcient of variation (CV) (N = 15)
of the determination were 4.1% and 5.0% at
49.2 g/L, respectively. The detection limit was
11 mg/L. Urinary creatinine in the same morning
samples was measured in duplicate by a modiﬁed
Jaffe’s reaction (Crea, Roche) on a Modular ana-
lyzer (Roche) and the within-run (N = 40) and the
between-run CV (N = 15) of the determination
were 1.2 and 2.3% at 0.6 g/L, respectively. The
detection limit was 0.040 g/L. Both determina-
tions were performed on the same day of the
sample collection. The UACR (mg/g) was calcu-
lated by dividing the mean of the urinary albumin
values by the mean of the urinary creatinine con-
centration. The body mass index (BMI) of all
patients has been calculated because the popula-
tion with higher muscle mass have higher levels of
creatinine excretion [26].
Results
The characteristics of the arteriogenic and non-
arteriogenic ED patients are summarized in
Table 1. Out of the 78 males, based on the echo-
color-doppler examination results, 29 patients had
arteriogenic ED (mean age 42.1 years, range
26–62 years; mean BMI 23.4 Kg/m2, range 20.9–
25.6 Kg/m2) and 49 patients had non-arteriogenic
ED (mean age 45.0 years, range 24–61 years; mean
BMI 23.0 Kg/m2, range 20.2–25.5 Kg/m2). The
age and the BMI of the two groups were not
signiﬁcantly different (P = 0.213 and P = 0.312,
respectively). Mean PSV was 16.2 cm/sec (range
9–19 cm/sec) and 46.4 cm/sec (range 32–79 cm/
sec) in patients with arteriogenic and with non-
arteriogenic ED (P = 0.001), respectively. Mean
EDV was 4.11 cm/sec (range 0–6 cm/sec) and
2.18 cm/sec (range from -6 to +12 cm/sec)
in patients with arteriogenic and with non-
arteriogenic ED (P = 0.002), respectively. Mean RI
was 0.72 (range 0.63–0.79) and 0.95 (range 0.73–
1.2) in patients with arteriogenic and with non-
arteriogenic ED (P = 0.001), respectively. In the
ﬁrst group, IIEF values were: mean 11.20 (range
0–22); in the second group the respective ﬁgures
were 12.9 (range 0–21). There were no signiﬁcant
differences between the two groups (P = 0.289).
Undetectable levels of albuminuria in at least one
of the two determination were present in 20
(69.0%) patients with arteriogenic ED and in 40
(81.6%) of those with non-arteriogenic ED
(P = 0.267). In the 18 patients with detectable
UACR concentrations, the mean  SD UACR
was 38.6  27.9 mg/g (range 8–95 mg/g) and
52.2  41.8 mg/g (range 10–143 mg/g) in the ﬁrst
(9 patients) and in the second (9 patients) group,
respectively. UACR of arteriogenic ED patients
were not signiﬁcantly different from UACR of non
arteriogenic ED patients (P = 0.429). Even in the
patients with detectable UACR concentrations,
there was no correlation with IIEF scores in both
groups (P = 0.05).
Discussion
The small diameter of the cavernosal arteries and
the high content of endothelium and smooth
muscle on a per-gram tissue basis (compared with
Table 1 Characteristics of study participants on the basis of ED status
Characteristics Arteriogenic ED (n 29) Non-arteriogenic ED (n 49) P
Age, years 42.1 (26–62) 45.0 (24–61) 0.213
BMI, kg/m2 23.4 (20.9–25.6) 23.0 (20.2–25.5) 0.312
PSV, cm/sec 21.0 (10–25) 48.3 (36–79) 0.001
EDV, cm/sec 3.3 (0–9) 5.1 (-6+12) 0.039
RI 0.84 (0.63–0.89) 0.86 (0.73–0.90) 0.570
IIEF 11.2 (0–22) 12.9 (0–21) 0.289
Data are expressed as means (range). A value of P < 0.05 was considered significant.
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other organs) may make the penile vascular bed a
sensitive indicator of systemic vascular disease
[27]. A normal erectile function requires a healthy
endothelial function [28]. Endothelial dysfunction,
which is associated with impaired release and
activity of NO, therefore, can be a cause of vascu-
lar ED [29,30]; through the same system, endot-
helial dysfunction is the physiologic connection
between ED and systemic vascular disease [31,32].
As previously mentioned, microalbuminuria is
considered as a marker of extensive endothelial
dysfunction. In the Steno hypothesis put forward
by Deckert [21], albumin leakage into the urine is
a reﬂection of widespread vascular damage. In a
sense, the kidney is the window of the vasculature.
In view of these considerations, endothelial func-
tion and chronic inﬂammation have been sug-
gested as possible candidates to explain the
association between microalbuminuria and cardio-
vascular diseases [33,34]. However, other studies
indicate that although microalbuminuria, endot-
helial dysfunction, and low-grade inﬂammation
are linked, they all are independently associated
with risk for cardiovascular death [35,36].
In our present search for a sensitive marker of
endothelial dysfunction in ED patients, the aim
of our study was to check if a simple examination
like microalbuminuria could replace the dynamic
echo-color-doppler evaluation of the cavernosal
arteries in discriminating the arteriogenic from
the non-arteriogenic ED subjects. Our results do
not support a role of microalbuminuria as a
screening method. In line with this evidence,
recently conducted studies that measured early
markers of cardiovascular diseases and endothe-
lial dysfunction (ﬂow mediated-vasodilation and
soluble P-selectine), demonstrated that damage
to the penile vascular bed occurs before systemic
vascular illness becomes clinically apparent
[37–39].
Conclusion
Our study shows that in ED patients without clini-
cal evidence of atherosclerotic diseases, and free of
the common risk factors associated with general-
ized penile arterial insufﬁciency, the cavernosal
arteries damage, as assessed by dynamic echo-
color-doppler, may be independent on or may
precede extensive endothelial dysfunction. In
addition, in this kind of ED patients microalbu-
minuria expressed as UACR cannot be predictive
of pure penile arteriogenic etiology, at least in our
experimental conditions. In general, no relation-
ship was shown between ED and microalbumi-
nuria in patients without any other known clinical
pathology.
This preliminary study shows that urinary
microalbumin expressed as UACR would be
unsatisfactory for the prediction of ED of arte-
riogenic etiology, at least in our experimental
conditions.
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